BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 15, 2019
View Archived Issues
Inducing HER2 expression to sensitize tumors
Read More
Size matters for cell prowess
Read More
T cells ChAT with blood vessels via neurotransmitter
Read More
Debiopharm initiates phase II FUZE study of Debio-1347
Read More
Vertex presents positive phase III study data for tezacaftor/ivacaftor
Read More
Advaxis initiates phase I/II study of ADXS-503 in patients with NSCLC
Read More
Phase III studies of brexpiprazole in patients with bipolar I disorder do not meet primary endpoint
Read More
KA-11 demonstrates promising activity in preclinical models of epilepsy and pain
Read More
MELK as a novel therapeutic target for neuroblastoma
Read More
University of Utah, Stingray Therapeutics patent E-NPP 1 inhibitors/STING modulators
Read More
ChemoCentryx synthesizes new PD-1/PD-L1 interaction inhibitors
Read More
New PAI-1 inhibitors presented by Eastern Michigan University and the University of Michigan
Read More
IL-13Ralpha2 as a novel marker and potential therapeutic target for malignant melanoma
Read More
The Helleday Foundation describes ADP-sugar pyrophosphatase inhibitors
Read More
New selective estrogen receptor degradation inducers patented by Zeno Royalties & Milestones
Read More
Loss of miR-7 facilitates gastric cancer metastasis: a potential biomarker and therapeutic target
Read More
TRIM14 promotes tumor invasion in glioblastoma, and may be a novel therapeutic target
Read More
AbCellera Biologics and Novartis enter multitarget collaboration
Read More
Forbius enters collaboration to evaluate TGF-beta inhibitor in myelofibrosis
Read More
Kymab begins phase I/II study of KY-1044 and atezolizumab in advanced cancers
Read More
PellePharm initiates phase III study of patidegib topical gel in basal cell nevus syndrome
Read More
Transgenic mouse model allows differentiation of platelet and leukocyte functions
Read More
ApoE-complement link opens door for new targets in Alzheimer's, atherosclerosis
Read More
New 64-week data reported from phase III study of Crysvita in X-linked hypophosphatemia
Read More